Home > Insider Trading > Filing (0001209191-11-051842)

Filing Details

Accession Number:: 0001209191-11-051842
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-10-17 17:12:23
Reporting Period:: 2011-10-13

Filing Date:: 2011-10-17
Accepted Time:: 2011-10-17 17:12:23
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1135906	Zalicus Inc.	ZLCS	Pharmaceutical Preparations (2834)	043514457

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1173408	L.p. Iii Bioventures Mpm	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1173409	L.p. Iii-Qp Bioventures Mpm	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249063	Mpm Bioventures Iii Parallel Fund, L.p.	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249133	Mpm Bioventures Iii Gmbh & Co. Beteiligungs Kg	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249141	Mpm Asset Management Investors 2003 Bviii Llc	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249143	L.p. Gp Iii Bioventures Mpm	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249147	Mpm Bioventures Iii Llc	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1263048	Mpm Asset Management Llc	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2011-10-13	5,000	$1.02	12,995,229	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2011-10-14	39,700	$1.02	12,955,529	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The shares were sold as follows: 4,141 by MPM BioVentures III-QP, L.P. ("BV III QP"), 278 by MPM BioVentures III, L.P. ("BV III"), 80 by MPM Asset Management Investors 2003 BVIII LLC ("AM 2003"), 125 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel"), 350 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG") and 26 by MPM Asset Management LLC ("MPM AM").
The shares are held as follows: 10,763,757 by BV III QP, 722,561 by BV III, 208,101 by AM 2003, 324,083 by BV Parallel, 908,425 by BV KG and 68,302 by MPM AM. MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III and BV Parallel and BV KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the members of MPM III LLC and AM 2003. Luke Evnin and Ansbert Gadicke are members of MPM AM. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.
The shares were sold as follows: 32,875 by BV III QP, 2,210 by BV III, 637 by AM 2003, 993 by BV Parallel, 2,778 by BV KG and 207 by MPM AM.
Represents weighted average sales price. The shares were sold at prices ranging from $1.02 to $1.03. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The shares are held as follows: 10,730,882 by BV III QP, 720,351 by BV III, 207,464 by AM 2003, 323,090 by BV Parallel, 905,647 by BV KG and 68,095 by MPM AM. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.